Ochsner announces cancer & COVID-19 mortality study findings
Published 12:00 am Wednesday, November 11, 2020
NEW ORLEANS – The Ochsner Cancer Institute announced key findings from a retrospective study comparing COVID-19 mortality rates in positive patients with and without cancer in Louisiana. It was published last week in the prestigious oncology journal, Cancer. The study evaluated 312 Ochsner Health cancer patients who tested positive for COVID-19 between March 1 and April 30 and compared that group’s mortality rates with 4,833 Ochsner Health COVID-19-positive patients without cancer during that same time period.
This is the largest study of COVID-19-positive patients with cancer versus patients without cancer to date and is the first multivariate analysis study comparing these two patient populations. It was an observational analysis that included 36 different Ochsner Health hospitals and clinics across Louisiana. To meet the criteria to be included in the non-cancer population studied, adult patients had to have at least one encounter in the Ochsner Health system between Jan. 1, 2019 and the date of their COVID-19 test and no cancer diagnosis recorded between Jan. 1, 2019 and the date of their COVID-19 test.
- In the study’s cohort of patients with cancer who were also infected with COVID-19, the mortality rate was 21.2 percent. In the non-cancer group, the COVID-19 mortality rate was 8.7 percent.
- Patients with cancer who are 65 years of age or older and those with certain comorbidities have the greatest risk of death.
- Patients with cancer and a history of smoking are four times more likely to die from COVID-19.
- Recent cancer-directed therapy, type of cancer and disease progression also played roles in mortality. This is the first study that suggests cancer patients receiving recent cancer-directed therapy are at increased risk of death.
- Patients with a hematologic cancer (leukemia, lymphoma and other blood-related cancers) had a 31.1 percent increased mortality versus patients with an oncologic malignancy (breast, prostate and other cancerous masses) who had an 18.7 percent increase in mortality.
- 4 percent of patients who died had active or progressive cancer at the time of infection and 17.7 percent died during post-treatment follow-up or maintenance therapy.
- Those with a recent diagnosis were more likely to die than those with a distant history of cancer (32.8 percent vs. 12 percent).
- Although the majority of patients studied in the cancer population were non-Hispanic Black (63.1 percent), mortality was not statistically affected by race.
What the Study Tells Us
It confirms that patients with cancer are at increased risk of death from COVID-19 and there is great potential and necessity to create and adopt strategies to protect this population in future outbreaks.
The COVID-19 pandemic has affected millions of people worldwide and New Orleans was an early hotspot in the virus’ initial emergence in the U.S. According to Ochsner oncology researchers, the impact on cancer patients is an important area of investigation. Cancer is the second most common cause of death globally and Louisiana has the ninth-highest incident rate of cancer in the country, according to the U.S. Centers for Disease Control. This made the state a unique population to study during this global pandemic.
Both the study and the published article were written by Principal Investigator Michael Lunski, MD, hematology/medical oncology fellow at The Gayle and Tom Benson Cancer Center at Ochsner Medical Center in New Orleans. Dr. Lunski’s contributing authors included: Jeffrey Burton, PhD, Karine Tawagi, MD, Diana Maslov, MD, Victoria Simenson, MD, Daniel Barr, MS-III, Helen Yuan, MD, Daniel Johnson, MD, Marc Matrana, MD, John Cole, MD, Zoe Larned, MD and Brian Moore, MD.
“Although patient-derived data from the COVID-19 pandemic is constantly changing, it is clear that the cancer patient population is at increased risk compared to those without cancer,” said Dr. Lunski. “Because we now have data showing that patients on active therapy are at an even more increased risk, extra efforts to protect these patients must be made.”
The Ochsner Cancer Institute, like all Ochsner Health hospitals and clinics, has established “Safe to Return” guidelines for patients undergoing cancer-directed therapy to ensure patient safety while providing optimal cancer care.
Dr. Lunski advises: “It is critical that people do not delay their medical care and that includes routine cancer screenings. Since we know that those with cancer are at increased risk for death from COVID-19, our primary goal is to prevent a cancer diagnosis or catch it at its earliest stage to further reduce someone’s risk of the severest consequence of this virus. It’s important to talk with a doctor about when and how often cancer screenings should be done.”
Cancer Care at Ochsner
The Ochsner Cancer Institute has cared for patients from all 50 states and 28 countries at its comprehensive cancer centers located throughout the New Orleans region, St. Tammany Parish, Baton Rouge, Lafayette, Southwest Louisiana and North Louisiana. In 2019, Ochsner served more than 32,000 adult and pediatric cancer patients. Five-year cancer survival rates for those treated at Ochsner continue to exceed the national average not only for the four major cancer malignancies of breast, colon, lung and prostate, but also several other types, including melanoma, head and neck, pancreatic, ovarian and cervical cancers.
Lunski, Michael and Burton, Jeffrey and Tawagi, Karine and Maslov, Diana and Simenson, Victoria and Barr, Daniel and Yuan, Helen and Johnson, Daniel and Matrana, Marc and Cole, John and Larned, Zoe and Moore, Brian, Multivariate Mortality Analyses in COVID-19: Comparing Patients With Cancer and Patients Without Cancer in Louisiana (10/28/2020). Available at: https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.33243